Tarrytown, NY based Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biopharmaceutical company focused on the discovery, development and commercialization of products for the treatment of serious medical conditions including eye diseases and high LDL cholesterol among others. Currently, the company has three marketed products in its portfolio – Eylea, Arcalyst and Praluent.
Eye drug, Eylea, should continue to remain the key growth driver contributing significantly to the top line. Meanwhile, Regeneron received a major boost when its PCSK9 inhibitor, Praluent, which the company has co-developed with Sanofi (PA:SASY), gained approval in the U.S. The cholesterol management market represents huge commercial potential and Praluent is expected to generate blockbuster sales.
In this scenario, investor focus remains on the performance of Eylea and Praluent apart from the usual top-and bottom-line numbers.
Regeneron’s performance has been far from impressive with the company missing earnings estimates in three of the trailing four quarters. Overall, the company has delivered an average negative earnings surprise of 9.27%.
Currently, Regeneron has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Regeneron’s first-quarter 2016 earnings fell short of expectations. Our consensus called for EPS of $1.37 and the company reported EPS of $1.32 (including share-based compensation expenses).
Revenues: However, revenues in the reported quarter came in slightly above expectations. Regeneron posted revenues of $1.20 billion, compared to our consensus estimate of $1.18 billion.
Key Stats: Regeneron’s revenues increased 38% year over year, benefiting from strong Eylea sales. Regeneron raised Eylea U.S. net sales guidance for 2016. The company now expects U.S. Eylea net sales to grow 20–25% year over year. Previously, it had anticipated Eylea sales to grow approximately 20% year over year.
Check back later for our full write up on this Regeneron earnings report later!
REGENERON PHARM (REGN): Free Stock Analysis Report
Original post
Zacks Investment Research